Draganfly Inc., a leading drone solutions developer, will host its third quarter 2026 shareholder update and earnings call on November 10, 2026, at 5:30 p.m. EST. CEO Cameron Chell will discuss recent company milestones and strategic direction, while CFO Paul Sun will review financial results for the quarter ending September 30, 2026. The company plans to release its Q3 financial results at market close on the same day. Investors can register for the call and submit questions in advance for discussion.
Draganfly's upcoming Q3 2026 shareholder update call is noted here alongside Pluang's Technology-sector market snapshot as of Nov 06, 2026 19:42 WIB. Of 150 priced US tech stocks on Pluang, 86 rose and 60 fell today. Notable movers include Workiva Inc (WK) down 12.42% at USD 74.81 with a typical hold time of 22 days, ASE Technology Holding Co Ltd (ASX) up 11.17% at USD 33.04 with 54% buy order activity, and Lam Research Corporation (LRCX) up 11.10% at USD 205.75 with 64% sell order activity and a 61-day typical hold time.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
